Wire · opportunities
Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 September 2026 · Fusion42 review
Matricelf received FDA feedback agreeing with key elements of its proposed first in human clinical trial design for NewRal, an autologous neural tissue therapy for spinal cord injury. The FDA endorsed the patient population, single-arm trial design, primary safety assessments, and exploratory efficacy measures, while requesting additional details for a future IND submission.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now plan your spinal cord injury therapy trials with FDA-aligned endpoints and patient criteria. Matricelf's FDA feedback opens the door for a clearer path to start clinical testing, reducing early regulatory uncertainty.
◆ Coverage
1 source · 3 Sep 2026
◆ Related on Wire
◆ Topics